Menopause Leave Laws by Country: Where the Right Exists in 2026

The Workplace Issue Nobody Legislated Until Recently

Roughly half the population will go through menopause. The transition lasts an average of seven years, can begin in the late 30s, and produces symptoms -- hot flashes, sleep disruption, brain fog, joint pain, anxiety -- that affect work performance for a meaningful share of those who experience them. The Fawcett Society's 2022 Menopause and the Workplace report found that one in ten women who worked during menopause had left a job because of their symptoms, with another 14% reducing hours, 14% going part-time, and 8% declining to apply for promotion.

For an issue affecting that many workers for that long, the legislative response has been remarkably thin. As of May 2026, no country in the world has a stand-alone federal menopause leave statute that creates a specific, named right to take time off for menopausal symptoms. Every protection that exists comes through other doors -- equality law, disability law, generic sick leave, or paid family and medical leave programs broad enough to absorb menopause-related medical absences.

That is changing -- but not evenly, and not in the places you would expect. The UK has built a useful body of disability-route case law under the Equality Act. Rhode Island became the first US jurisdiction in the world to legislate menopause as a named ground for workplace accommodation in June 2025. Spain passed Europe's first menstrual-leave statute in 2023, though its menopause coverage is narrower than the headlines suggested. Australia's Senate inquiry produced 25 recommendations in September 2024, but the follow-up bill is stalled. Several US state bills have been introduced but mostly not advanced.

This article walks through the frameworks, names the cases and statutes you can actually rely on, and -- because the question the title implies is which of these is working -- ends with a section on which legal regimes are delivering measurable outcomes for workers and which are doing legislative theater.

This article provides general information about leave rights. It is not legal advice. For your specific situation, consult an employment attorney or your relevant labor authority.

The UK: Closest to a Right, Through the Equality Act

The United Kingdom has gone further than any other major economy in establishing menopause workplace protections, though the route it took is indirect. There is no UK statute called the "Menopause Leave Act." Instead, protections have emerged through case law applying the Equality Act 2010 to menopausal symptoms, combined with regulator and parliamentary guidance.

The Equality Act protects against discrimination on three grounds relevant to menopause: sex, age, and disability. The disability route has been most productive. Under section 6 of the Equality Act, a person is disabled if they have "a physical or mental impairment" that has "a substantial and long-term adverse effect on [their] ability to carry out normal day-to-day activities." Where menopausal symptoms meet that test -- substantial, long-term, affecting normal activities -- tribunals have repeatedly held they fall within scope. The most cited cases:

• Davies v Scottish Courts and Tribunals Service (2018): the Glasgow Employment Tribunal held that the claimant's severe menopausal symptoms (heavy bleeding causing anaemia, brain fog, concentration loss) amounted to a disability, and that her dismissal -- arising from a confused incident in which she had been prescribed a granulated medication -- was discrimination arising from disability under section 15 of the Equality Act. The SCTS was ordered to reinstate her and pay roughly £19,000.
• Donnachie v Telent Technology Services (2020): the tribunal explicitly rejected the employer's argument that "typical" menopausal symptoms (hot flushes seven to eight times per day, palpitations, anxiety, fatigue, concentration issues) were not substantial enough to qualify. Judgment: "I see no reason why, in principle, 'typical' menopausal symptoms cannot have the relevant disabling effect on an individual."
• Rooney v Leicester City Council (EAT, 2021): the Employment Appeal Tribunal overturned the lower tribunal's strike-out of the disability and sex discrimination claims and remitted them for fresh consideration, holding that the tribunal had erred by focusing on what the claimant could do without weighing what she could not. Significant for appellate-level recognition that menopausal symptoms can in principle amount to a disability under the Equality Act, though the EAT did not itself make a final disability finding.

The practical effect: UK workers with significant menopausal symptoms can request reasonable adjustments under disability discrimination law -- time off, schedule flexibility, environmental modifications (cooler workspaces, fan provision), reduced workload during difficult periods. Employers who refuse to engage risk a discrimination claim with real damages.

The 2022 Menopause and the Workplace report by the Women and Equalities Committee called on the UK government to legislate menopause as a separate protected characteristic and to pilot a menopause leave provision. The government rejected both in its January 2023 response, arguing that the existing protected characteristics of sex, age, and disability already covered the ground and that adding menopause separately could "create new forms of discrimination" or erode existing protections. The committee called the response a "missed opportunity." Whether you call it that depends on whether the existing three-ground framework is actually delivering -- which it largely is, in tribunal damages and behavioural change, even without a named statute.

What did move: a government-appointed Menopause Employment Champion in 2023, ACAS guidance on menopause at work, Health and Safety Executive risk-assessment material, and -- the most prominent regulator-level document -- the Equality and Human Rights Commission menopause workplace guidance for employers published in February 2024.

The bottom line for UK workers in 2026: there is no menopause leave statute, but the Equality Act provides a meaningful framework, supported by a growing body of tribunal decisions, that workers can use -- particularly when symptoms rise to the disability threshold.

Spain: First in Europe, Narrower Than the Headlines

Spain became the first European country to legislate paid leave for incapacitating menstrual symptoms when Ley Orgánica 1/2023 was passed in February 2023. The law allows workers with secondary incapacitating menstruation to take paid leave with a doctor's certification, paid by the social security system rather than the employer.

The "first in Europe" framing was earned, but the substantive scope is narrower than international coverage suggested. The leave provision is tied specifically to secondary dysmenorrhea -- painful menstruation arising from a previously diagnosed pathology such as endometriosis. It is not a menstrual leave for everyone with painful periods, and it does not, on the face of the statute, provide a leave entitlement for menopausal symptoms. Menopause is mentioned in the law, but only in the healthcare and education sections (specialist care for women in the climacteric and menopausal phase), not in the leave provision itself.

Workers in Spain experiencing severe menopausal symptoms therefore still rely on the same generic mechanism that workers across the rest of Europe use: medical certification and statutory sick leave. The named menstrual-leave statute is symbolically important, and the social-security funding model (rather than employer cost) is genuinely worth studying. But it is not, in 2026, a menopause leave law. Several other EU countries have introduced bills along similar lines; none have passed comparable legislation.

Australia: A Senate Inquiry, a Stalled Bill, and a Right-to-Request That Hasn't Arrived

Australia held a Senate Community Affairs References Committee inquiry titled "Issues related to menopause and perimenopause" that reported in September 2024 with 25 recommendations. The committee did not recommend a named menopause leave entitlement. Recommendation 6 proposed amending the Fair Work Act to enable flexible working arrangements during menopause; recommendation 8 asked the government to research the impact and effectiveness of sexual and reproductive health leave more broadly.

The legislative follow-up came as a Greens private member's bill: the Fair Work Amendment (Paid Reproductive Health Leave and Flexible Work Arrangements) Bill 2025, introduced by Senator Larissa Waters on 26 March 2025. It would create 12 days of paid reproductive health leave per year and add menopause and perimenopause symptoms to the grounds for requesting flexible working under the Fair Work Act. The bill lapsed at the end of the parliamentary term in July 2025 and was restored to the Notice Paper, but has not advanced beyond second reading. As of May 2026 it remains pending.

For private-sector Australian workers in 2026, the practical position is the pre-Equality-Act-case-law UK position: protections sit in general anti-discrimination law -- the Sex Discrimination Act 1984 (which does not name menopause) and the Disability Discrimination Act -- and in generic personal/carer's leave under the Fair Work Act. Some state and territory governments have moved at the public-sector level, with menopause-supportive provisions appearing in some Victorian public sector enterprise agreements. The Senate inquiry shifted the conversation, and the Fair Work Ombudsman and Australian Human Rights Commission have produced employer guidance, but the statute book has not yet caught up.

The United States: ADA, Title VII, and Rhode Island as the Outlier

There is no federal US menopause leave statute. Federal protection runs through three frameworks: Title VII of the Civil Rights Act (sex discrimination), the Americans with Disabilities Act (where symptoms substantially limit a major life activity), and the Age Discrimination in Employment Act (where age-related stereotyping intersects with menopause).

The ADA is the most directly relevant for accommodations or leave. The EEOC has not issued menopause-specific guidance, but its general framework for chronic medical conditions applies. Where menopausal symptoms substantially limit a major life activity -- sleeping, concentrating, working, thermoregulation, or related functions -- the worker may qualify for ADA reasonable accommodations, which can include schedule flexibility, remote work, climate-controlled workspaces, modified break schedules, and time off as a last resort. Federal courts have not produced a developed body of menopause-specific ADA case law; the doctrine has been applied unevenly and case-by-case.

The state-level picture changed in 2025. Rhode Island Governor Daniel McKee signed House Bill 6161 on 24 June 2025, making Rhode Island the first US state -- and the first jurisdiction in the world -- to expressly require employers to provide reasonable accommodations for menopause and related medical conditions. The law amends the Rhode Island Fair Employment Practices Act to include menopause and "the need to manage the effects of vasomotor symptoms" (hot flashes, night sweats) as grounds for workplace accommodation, effective immediately on signing. Employers with four or more employees must engage in a timely, good-faith interactive process and post written notice of employee rights. This is an accommodation mandate, not a paid-leave statute, but it is the most explicit menopause-as-protected-condition law on any books anywhere as of 2026.

No other US state has matched Rhode Island. Bills have been introduced in California, New York, Massachusetts, and elsewhere in recent sessions and have generally not advanced. Some states' broader paid family and medical leave programs (covered in our FMLA interaction guide) can be used for menopause-related medical conditions where they meet the program's "serious health condition" threshold.

For US workers in 2026: the ADA is the strongest federal lever, state PFML programs can fund the most severe cases, Rhode Island is the only state with explicit menopause protection, and employer policies vary widely. Several large employers (Google, Microsoft, Adobe, Genentech, and others) have introduced menopause-specific benefits voluntarily.

The Rest of Europe: Patchwork Through Sick Leave

Most European countries provide reasonably generous statutory sick leave with strong wage replacement. Menopausal symptoms severe enough to warrant a doctor's certification are typically covered without a menopause-specific statute. The mechanism is generic sick leave; access is medical documentation.

The pattern in continental Europe is that the floor is high enough that menopause-specific legislation has not been a top legislative priority -- generic sick leave fills the gap reasonably well for severe symptoms. Where Europe has moved toward menopause-specific policy, it has tended to be through national workplace health frameworks and employer guidance rather than dedicated statutes.

Asia and Japan: Cultural Silence, Limited Frameworks

Menopause workplace protections in Asia are generally limited, both in legal frameworks and in cultural willingness to discuss the issue at work. There is no menopause-specific leave statute in any major Asian economy. The cultural taboo around discussing menopause at work in many Asian workplaces means that even where general sick leave is available, uptake is low.

The most notable points:

• Japan: the Industrial Safety and Health Act and various workplace health regulations require general health management programs, and some large employers have introduced menopause-specific provisions as part of broader women's health initiatives. Uptake remains limited.
• South Korea: maternity and women's health protections are well-developed in statute, but menopause is not a named category. Generic sick leave applies.
• Singapore: the Tripartite Standards on Flexible Work Arrangements provide a framework that has been used by some employers to support menopausal employees, but no specific legislative right exists.
• Hong Kong, Taiwan, mainland China: menopause is not addressed in workplace law as a specific category, and uptake of generic sick leave for menopausal symptoms is culturally limited.

Companies Leading Where Governments Lag

The most concrete menopause workplace protections in 2026 often come not from governments but from individual employers. A growing list of large companies has introduced menopause-specific policies that approximate what a future statute might require. Notable examples:

The pattern across these policies is consistent: time off when needed, accommodations when working through it, manager training to remove the conversation friction, and medical support layered on top. Workers at companies with these policies have a meaningful right to menopause leave even where their country's law does not yet provide one.

For workers at companies without such a policy, the question becomes how to request something approximating it through existing leave categories.

How to Request Time Off When No Statute Names It

In a country without menopause-specific legislation, the practical path to leave for menopausal symptoms is one of three routes:

Route 1: Sick leave with medical certification. The most common path. A GP or specialist provides a certification that the worker is unfit for work due to medical symptoms. The employer is generally not entitled to know the specific diagnosis -- "medical condition causing incapacity" is sufficient on most certifications. Sick leave is then accessed through the standard process.

Route 2: Disability accommodation request. In jurisdictions with disability discrimination frameworks (the UK Equality Act, the US ADA, Canada's accommodation framework, Australia's DDA), a request for reasonable accommodation can be made on the basis that menopausal symptoms substantially affect the ability to work. The accommodation can include time off when needed, schedule flexibility, environmental modifications, or remote work. The employer's duty to engage in an interactive process is the legal hook. We have written about the parallel ADA accommodation framework that applies to many other conditions.

Route 3: Generic personal/PTO leave. Where the first two routes are unavailable or unwelcome, generic personal time off remains an option. The drawback is that it depletes the same PTO bank used for vacation and bridge days. The advantage is that no medical disclosure is required. Some workers prefer this route specifically to avoid disclosing menopausal status to their employer.

The typical pattern when all three are available: workers use accommodation requests for ongoing flexibility, sick leave for severe symptom days, and personal PTO for the gaps. Combining the three minimizes both the impact on PTO and the friction of disclosure.

A few additional practical notes:

• Documentation is your friend. The same discipline that supports any contested leave request applies here. Save communications, keep medical records organized, document the timeline.
• Request templates help. Our time-off email templates can be adapted for menopause-related requests, particularly the medical-condition framing that does not require disclosure of specifics.
• Manager conversations are easier than HR conversations. Where a sympathetic manager exists, work the manager route first. HR processes tend to be more rigid and may force more formal disclosure than a private manager conversation requires.
• Know your country's framework before you need it. The legal lever you can use depends on the jurisdiction. UK and Rhode Island workers have explicit accommodation routes. Australian and Canadian workers have strong disability-route options. US workers outside Rhode Island have stronger PFML routes in California, New York, Massachusetts, Washington, and a handful of other states than they have direct menopause protection.

Where the Law Actually Works in Practice

The question the title of this article implies is which framework is working -- and the answer in 2026 is not the one the headlines suggest. Here is the editorial take, drawn from what the case law and the statute book actually say.

1. The UK disability-route is the framework moving the most money to workers, even without a named statute. Davies got reinstated and roughly £19,000. Donnachie established that "typical" menopausal symptoms can meet the disability threshold, foreclosing the employer defence that hot flushes and brain fog are too ordinary to count. Rooney got the appellate-level recognition that strike-outs of menopause discrimination claims will be reviewed seriously. Combined with EHRC employer guidance and a parliamentary report that, even in being rejected, generated a Menopause Employment Champion and an HSE risk-assessment framework, the UK's three-ground Equality Act regime is delivering enforceable outcomes year after year. The UK government's January 2023 rejection of menopause-as-separate-protected-characteristic is more defensible than the press coverage allowed: the existing framework was already covering the ground. Adding a fourth ground would have generated litigation about scope without obviously expanding remedies.

2. Spain's named menstrual-leave statute is narrower in practice than its symbolism. Ley Orgánica 1/2023 covers secondary dysmenorrhea tied to a previously diagnosed pathology. It is not a general menstrual-leave law, and on the face of the statute it does not provide a leave entitlement for menopausal symptoms. The social-security funding model (rather than employer cost) is genuinely worth copying. The named statute itself, if you measure by direct menopause coverage, does less work than a generic sick-leave system with a doctor's note -- which Spain already had. Naming a thing in legislation is not the same as covering it.

3. The US is the jurisdiction with the largest gap between need and statute, and Rhode Island just illuminated the right path forward. A federal ADA accommodation case for menopause is a litigation-by-litigation slog in a regime where "natural consequence of aging" is a defendable employer position and menopause-specific case law is thin. Rhode Island's June 2025 statute is the first US framework to put menopause and vasomotor symptoms by name into a state Fair Employment Practices Act, mandating an interactive accommodation process from any employer with four or more workers. It is an accommodation mandate, not a paid-leave statute, but that is arguably the more useful tool: most workers who quit during menopause quit because their work environment did not bend, not because they ran out of paid sick days. Other US states should copy Rhode Island before they pursue paid menopause leave.

4. Australia is consultation theater until a bill passes. A Senate inquiry, 25 recommendations, a stalled Greens private member's bill, and Fair Work Ombudsman guidance amount to a conversation, not a legal change. Until the Fair Work Act is amended to put menopause and perimenopause into the right-to-request-flexible-working list -- or until a national accommodation mandate equivalent to Rhode Island's appears -- the Australian framework runs on the same generic anti-discrimination law that has been there for forty years.

5. The named-statute approach is overrated; the disability-framework-with-tribunal-pipeline approach is underrated. A statute that names "menopause leave" but ties it to narrow eligibility (Spain's pathology requirement) or has no enforcement teeth pays out less than a broad disability-discrimination regime with a working tribunal system and a regulator publishing employer guidance. The UK has the latter. Rhode Island built a narrow but enforceable version of the latter. Spain has the former. The win condition is enforceability, not naming.

The trajectory across all developed economies is upward. The legal frameworks are more real than they were five years ago, the accommodation routes work in practice in most developed countries, and corporate pressure to formalize policies is increasing. The major remaining gap is between countries with a working enforcement pipeline and those running on guidance documents alone.

Disclaimer

This article summarizes menopause workplace-law frameworks across multiple jurisdictions as of May 2026. This is one of the fastest-evolving areas of employment law: UK tribunal case law shifts each year, Australia is consulting on national menopause workplace protections, the EU and individual member states are debating reproductive-health-leave statutes, and US state legislatures see new bills each session. Individual employer policies, collective bargaining agreements, and union contracts may also grant additional rights.

Use this article as a starting point, not a legal opinion. Before making decisions:

• For UK rules, check gov.uk, ACAS menopause guidance, and EHRC
• For Australian rules, check Fair Work Ombudsman and the Australian Human Rights Commission
• For US rules, check the EEOC and your state labor department
• For EU/EEA rules, check your national labor ministry
• Read your employer's specific menopause / reproductive health / disability accommodation policies
• Consult a qualified employment attorney for situations involving denied accommodations or termination

Nothing in this article constitutes legal advice or creates an attorney-client relationship.

Try the free optimizer at leavewise.co

If you are navigating menopause alongside a typical year of bridge days, school holidays, and the rest of normal leave planning, the optimizer can help you map out what your full year looks like with the additional medical days factored in. Symptom-related leave is unpredictable, but the rest of the year does not have to be. Knowing how the math works on the days you can plan makes the days you cannot plan easier to absorb.